Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.44 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116174 | 0.98 | GRIK1 (0.46) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL16135497 | 0.98 | GRIK1 (0.46) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL342491 | 0.85 | GRIK1 (0.53) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| Potassium Ion SCHEMBL16116168 | 0.82 | GRIK1 (0.39) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL12162469 | 0.75 | GRIK1 (0.40) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL1405553 | 0.75 | GRIK1 (0.40) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL9241910 | 0.72 | GRIK1 (0.38) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL7046565 | 0.71 | SMN1; SMN2 (0.44) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL17468413 | 0.71 | GRIK1 (0.37) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL16114942 | 0.70 | GRIK1 (0.38) | GRIK1GRIA2GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2978748-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | Pfizer Ireland Pharmaceuticals (IE) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| CN-105051022-A | Process and intermediates for the preparation of pregabalin | PFIZER IRELAND PHARMACEUTICALS | 2015-11-11 | — | — | CN | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | GABRE, GABRG1, GABRG2 | GRIK1 311/4885GRIA2 259/4885GRIA4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.